Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin.

ABSTRACT:

Background

Since the discovery of streptomycin in the 1940s, more than a dozen drugs have been continuously introduced into tuberculosis (TB) therapy. However, limited attention has been paid to the collateral effects of drug resistance evolution in Mycobacterium tuberculosis (Mtb). Recently, we observed a clear discordance between the capreomycin (CAP) susceptibility of rifampicin-resistant (RR) Mtb clinical isolates and the adverse outcomes associated with CAP treatment, indicating potential collateral effects between rpoB mutations and CAP. To explore this relationship, we integrated clinical isolate data, experimental evolution data, phenotypic data, sequencing data, and genome-wide association studies (GWAS).

Methods

We analysed the correlations between CAP resistance a

SUBMITTER: Xu JT 

PROVIDER: S-EPMC12166843 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature